Latest Trials Latest NewsFAQ

Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Phase 1

Terminated

Conditions: Triple Negative Breast Cancer
Advanced Ovarian Cancer

Interventions: Drug: Atezolizumab
Drug: RO6870810

First Posted Date: 2017-09-25

Last Posted Date: 2020-11-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 36

Registration Number: NCT03292172

Locations: 🇨🇦
University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada
🇺🇸
Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States
🇬🇧
The Christie, Manchester, United Kingdom

and more 8 locations

A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Glucocorticoid Agent

First Posted Date: 2017-09-25

Last Posted Date: 2020-05-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 101

Registration Number: NCT03291457

Locations: 🇧🇪
Private Practice Els Van Essche, Bonheiden, Belgium
🇧🇪
Rhumarc sciv sprl, Céroux-Mousty, Belgium
🇧🇪
CHC MontLégia, Liege, Belgium

and more 19 locations

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

Completed

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-Hodgkin

Interventions: Drug: MabThera

First Posted Date: 2017-09-20

Last Posted Date: 2021-01-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 701

Registration Number: NCT03289182

Locations: 🇰🇷
Pusan National University Yangsan Hospital, Gyeongsangnam-do, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of

and more 22 locations

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Phase 2

Terminated

Conditions: Polycythemia Vera

Interventions: Drug: Idasanutlin

First Posted Date: 2017-09-19

Last Posted Date: 2021-12-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 27

Registration Number: NCT03287245

Locations: 🇺🇸
University of Kansas Cancer Center; Westwood Cancer Center/BMT Output Clinic, Kansas City, Kansas, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
University of Texas Health Sciences Center in San Antonio, San Antonio, Texas, United States

and more 8 locations

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase 4

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Atezolizumab

First Posted Date: 2017-09-18

Last Posted Date: 2022-05-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 619

Registration Number: NCT03285763

Locations: 🇪🇸
Complejo Hospitalario de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain
🇬🇷
Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, Greece
🇮🇹
Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche, Roma, Lazio, Italy

and more 109 locations

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1

Active, not recruiting

Conditions: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

Interventions: Drug: 5-Fluorouracil (5-FU)
Biological: PEGylated recombinant human hyaluronidase (PEGPH20)
Drug: BL-8040
Biological: Ramucirumab
Drug: Linagliptin
Drug: Leucovorin
Drug: Cobimetinib
Drug: Paclitaxel
Drug: Cisplatin
Drug: Oxaliplatin
Drug: Tiragolumab
Drug: Atezolizumab

First Posted Date: 2017-09-13

Last Posted Date: 2024-10-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 410

Registration Number: NCT03281369

Locations: 🇺🇸
Uni of Southern California; Norris Comprehensive Cancer Ctr, Los Angeles, California, United States
🇺🇸
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇦🇺
Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia

and more 33 locations

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

Phase 3

Completed

Conditions: Nasal Polyps
Chronic Rhinosinusitis

Interventions: Drug: Placebo
Drug: Omalizumab

First Posted Date: 2017-09-12

Last Posted Date: 2020-03-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 138

Registration Number: NCT03280550

Locations: 🇺🇸
Northwell Health, Great Neck, New York, United States
🇨🇦
CHAUQ Hospital St Sacrement, Quebec, Canada
🇨🇦
Ottawa Allergy Research Corp, Ottawa, Ontario, Canada

and more 34 locations

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Drug: Ipatasertib
Drug: Entinostat
Drug: Fulvestrant
Drug: Bevacizumab
Drug: Exemestane
Drug: Abemaciclib
Drug: Tamoxifen

First Posted Date: 2017-09-12

Last Posted Date: 2024-10-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 138

Registration Number: NCT03280563

Locations: 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 24 locations

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps

Phase 3

Completed

Conditions: Nasal Polyps
Chronic Rhinosinusitis

Interventions: Drug: Placebo
Drug: Omalizumab

First Posted Date: 2017-09-12

Last Posted Date: 2020-03-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 127

Registration Number: NCT03280537

Locations: 🇪🇸
Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain
🇧🇪
UZ Gent, Gent, Belgium
🇵🇱
Synexus - Warsaw, Warszawa, Poland

and more 42 locations

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Phase 3

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Polatuzumab Vedotin
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine Placebo
Drug: Polatuzumab vedotin Placebo

First Posted Date: 2017-09-07

Last Posted Date: 2025-01-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1000

Registration Number: NCT03274492

Locations: 🇷🇺
Leningrad Regional Clinical Hospital, St Petersburg, Sankt Petersburg, Russian Federation
🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 213 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy